drugset / Trial / NCT00689507
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
Non-randomizedSingle-groupOpen-labelTreatment
Summary
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
Timeline
- Start
- 2008-03
- Primary completion
- 2013-01
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tabalumab | Monoclonal antibody | 1 mg | Intravenous |
| Subject | Tabalumab | Monoclonal antibody | 10 mg | Intravenous |
| Subject | Tabalumab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Tabalumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Tabalumab | Monoclonal antibody | 300 mg | Intravenous |